Prosecution Insights
Last updated: April 19, 2026
Application No. 18/261,751

ANALYSIS OF EMBEDDED TISSUE SAMPLES USING FLUORESCENCE-BASED DETECTION

Non-Final OA §103
Filed
Jul 17, 2023
Examiner
HON, MING Y
Art Unit
2666
Tech Center
2600 — Communications
Assignee
Agilent Technologies, Inc.
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
96%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allow Rate
624 granted / 760 resolved
+20.1% vs TC avg
Moderate +14% lift
Without
With
+13.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
23 currently pending
Career history
783
Total Applications
across all art units

Statute-Specific Performance

§101
12.0%
-28.0% vs TC avg
§103
62.7%
+22.7% vs TC avg
§102
8.2%
-31.8% vs TC avg
§112
10.9%
-29.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 760 resolved cases

Office Action

§103
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Election/Restrictions Applicant’s election without traverse of Claims 1-10, 13 and 14 in the reply filed on December 29, 2025 is acknowledged. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 1 is rejected under 35 U.S.C. 103 as being unpatentable over Schleifer US2019/0368982 in view of Gurevich et al. US2018/0028079 hereinafter referred to as Gurevich. As per Claim 1, Schleifer teaches a method of determining an amount of tissue or cell preparation exposed at a surface of a sample embedded in an embedding medium comprising: irradiating the embedded tissue or cell preparation sample at a wavelength which causes endogenous components of the tissue to autofluoresce; (Schleifer, Paragraph [0035], “Contrary to the present methods utilize autofluorescence of endogenous fluorophores in tissue to distinguish tissue from an embedding medium such as paraffin or an epoxy resin. Contrasting between tissue and an embedding medium can be achieved by irradiating an embedded sample such as a formalin-fixed paraffin-embedded (FFPE) tissue block at an appropriate wavelength, and detecting the resulting fluorescence emission”) obtaining an image of the autofluorescence emitted by the embedded tissue or cell preparation sample; and (Schleifer, Paragraph [0039], “the imaging device comprises a camera such as a digital camera. In such cases, an embedded sample comprising tissue and an embedding medium such as paraffin is irradiated with light and the resulting fluorescence emission is captured using a digital camera. The presence of fluorescence in the digital image provides an indication that tissue is present in the sample under study”) Schleifer does not teach determining a percentage of the image at the surface of the embedding medium which is occupied by tissue or cell preparation. Gurevich teaches determining a percentage of the image at the surface of the embedding medium which is occupied by tissue or cell preparation. (Gurevich, Paragraph [0157], “a new subject may be evaluated by generating the subject time series of fluorescence images of the tissue under evaluation during imaging, generating the subject spatial maps as was described herein, storing such map in a database or registry, storing various data derived from the map (e.g., statistical data derived from the map such as, for example, percentage of each cluster in the map, their mean/median/standard deviation, map histogram or a combination thereof)”) Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to implement the teachings of Gurevich into Schleifer because by providing means to gather statistical data of the fluorescence images will allow further processing to be performed utilizing the gathered statistical data. Therefore it would have been obvious to one of ordinary skill to combine the two references to obtain the invention in Claim 1. Allowable Subject Matter Claims 2-10 and 13-14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MING HON whose telephone number is (571)270-5245. The examiner can normally be reached M-F 9am - 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Terrell can be reached on 571-270-3717. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MING Y HON/Primary Examiner, Art Unit 2666
Read full office action

Prosecution Timeline

Jul 17, 2023
Application Filed
Feb 10, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12602904
METHOD AND ELECTRONIC DEVICE FOR RECOGNIZING OBJECT BASED ON MASK UPDATES
2y 5m to grant Granted Apr 14, 2026
Patent 12567244
METHOD AND APPARATUS FOR FUSING MULTI-SENSOR DATA
2y 5m to grant Granted Mar 03, 2026
Patent 12555240
BRUCH'S MEMBRANE SEGMENTATION IN OCT VOLUME
2y 5m to grant Granted Feb 17, 2026
Patent 12555411
Facial Emotion Recognition System
2y 5m to grant Granted Feb 17, 2026
Patent 12536838
PATCH-BASED ADVERSARIAL ATTACK DETECTION AND MITIGATION
2y 5m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
96%
With Interview (+13.8%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 760 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month